ABSTRACT
Objectives COVID-19 has had a substantial impact on rheumatology. This study provides a general overview of studies on rheumatology and COVID-19.
Methods Data were taken from the Web of Science (WoS) website. Analysis and network visualization mapping processes were carried out using VOSviewer. A total of 234 publications were analyzed, and the correlations between citation numbers and reference counts, usage counts and page numbers were analyzed with Spearman correlation coefficients.
Results The average number of citations per item was 6.03. The studies were cited 1,411 times in total, and 1,121 times without self-citations. The countries with the highest number of publications on rheumatology and COVID-19 were the USA and England; the countries with the highest number of citations were Italy and the USA, and Jinoos Yazdany was the most cited author. The Annals of the Rheumatic Diseases was the most cited journal, whereas the highest number of articles on rheumatology and COVID-19 were published in Arthritis and Rheumatology.
Conclusions Bibliometric analysis of rheumatology and COVID-19 can be useful to future studies because it provides a general perspective on the studies. This study provides an insight into the development of publications on rheumatology during the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
There no need to take a ethical approval. There was no attemption to humans or animals.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.